ClinicalTrials.gg
RecruitingNCT07460375Updated Oct 19, 2026

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

A Phase 1/2 interventional study of LCB02A in Advanced Solid Tumors, sponsored by LigaChem Biosciences, Inc.. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by LigaChem Biosciences, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 19, 2026Site recruiting status changedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
191
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Claudin 18.2
  • CLDN18.2
03

In context

Lead sponsor

LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Phase 1 Dose Escalation: or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and to standard of care treatment.
  • Phase 2 Dose Expansion: selected histologically or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and refractory to standard of care treatment. Expansion cohort indications will be prioritized based on data from the Phase 1 dose escalation portion.
  • Prior treatment with Claudin 18.2 directed therapy is permitted.
  • as defined by v1.1
  • Willingness to provide when available, or to undergo a pre-treatment biopsy if archival tissue is not available.
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function as defined by:

    • ≥ 1.5 × 109/L , without colony stimulating factor support for the past 14 days
    • count ≥ 100 × 109/L
    • level ≥ 9.0 g/dL
    • Total ≤ 1.5× (ULN) or \<3 x ULN with Gilbert's syndrome or liver at baseline
    • (AST)/alanine aminotransferase (ALT) ≤ 2.5× ULN (≤ 5.0× ULN for subjects with liver metastases)
    • Albumin ≥ 2.5 g/dL
    • ≥ 60 mL/min

Key Exclusion Criteria:

  • Prior exposure to ADCs with a Topo1 inhibitor payload.
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Note: Patients may be considered for enrollment if they have previously treated that are clinically stable or radiologically stable for at least 14 days prior to the first dose.

  • Received radiotherapy within 21 days prior to the first dose of study drug. Note: For palliative radiotherapy for symptomatic improvement of non-central nervous system (CNS) lesions (total duration of radiotherapy ≤ 14 days), a radiation of 7 days is required prior to the first dose.
  • Any medical conditions that may confound the study results, interfere with the patient's compliance, or impair the interests of the subject, as assessed by the Investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
191 participants (estimated)

Study arms

  • Experimental
    LCB02A monotherapy

    Drug: LCB02A

Interventions

  • DrugLCB02A

    CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload.

06

What researchers measure

Primary outcomes

  1. Safety of LCB02A (Phase 1 and 2)

    Incidence and severity of AEs

    Time frame: Up to 48 months

  2. Recommended Phase 2 dose of LCB02A (Phase 1)

    Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics

    Time frame: Up to 24 months

  3. Objective response rate (Phase 2)

    Assessed by RECIST 1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. Plasma concentrations of LCB02A (Phase 1 and 2)

    Pharmacokinetic parameters will be determined from observed concentrations of LCB02A

    Time frame: Up to 48 months

  2. Duration of Response (Phase 1 and 2)

    Assessed by RECIST v1.1

    Time frame: Up to 48 months

  3. Disease control rate (Phase 1 and Phase 2)

    Assessed by RECIST v1.1

    Time frame: Up to 48 months

  4. Progression Free Survival (Phase 1 and Phase 2)

    Assessed by RECIST v1.1

    Time frame: Up to 48 months

  5. Overall Survival (Phase 1 and Phase 2)

    Time frame: Up to 48 months

07

Study locations

2 of 8 sites recruiting
  • Mass General Hospital
    Boston, Massachusetts 02214, United States
    Not yet recruiting
    • Haeseong Park, MD · Principal investigator
  • START New York - Long Island
    Lake Success, New York 11042, United States
    Recruiting
    • Geraldine O'Sullivan Coyne, MD · Principal investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29406, United States
    Not yet recruiting
    • A. Craig Lockhart, MD · Principal investigator
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
    • Mariela Blum Murphy, MD · Principal investigator
  • Princess Margaret Hospital
    Toronto, Ontario M5S 3H2, Canada
    Recruiting
    • Erica Tsang, MD · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Not yet recruiting
    • Do-Youn Oh, MD · Principal investigator
  • ASAN Medical Center
    Seoul, 05505, South Korea
    Not yet recruiting
    • Min-Hee Ryu, MD · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Not yet recruiting
    • Minsuk Kwon, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Feb 2030, 40 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 10, 2026
StartActual
Oct 14, 2026was Aug 2026
Primary completionEst.
Feb 2030
CompletionEst.
Aug 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Princess Margaret Hospital is now Recruiting
Oct 19, 2026
Start date
Aug 2026→Oct 14, 2026 (actual)
Oct 19, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Mass General Hospital · Boston, United StatesContact person changed (no phone or email listed)
  • ASAN Medical Center · Seoul, South KoreaContact added (no phone or email listed)
  • Samsung Medical Center · Seoul, South KoreaContact added (no phone or email listed)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Princess Margaret Hospital is now Recruiting
    Start date Aug 2026→Oct 14, 2026 (now actual)
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Mass General Hospital · Boston, United StatesContact person changed (no phone or email listed)
    • ASAN Medical Center · Seoul, South KoreaContact added (no phone or email listed)
    • Samsung Medical Center · Seoul, South KoreaContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07460375
Lead sponsor
LigaChem Biosciences, Inc.
Collaborators
AntibodyChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Oct 14, 2026
Primary completion
Feb 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

David Browning
Contact
clinicaltrials@ligachembio.com
+1-615-975-7776
Rodrigo Ruiz Soto, M.D.
study director · LigaChem Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion